BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17382799)

  • 1. New molecular targets and novel agents in the treatment of advanced urothelial cancer.
    Beekman KW; Bradley D; Hussain M
    Semin Oncol; 2007 Apr; 34(2):154-64. PubMed ID: 17382799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of chemotherapy in advanced urothelial cancer.
    CalabrĂ² F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D; Pectasides M; Economopoulos T
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for relapsed small-cell lung cancer.
    Azim HA; Ganti AK
    Anticancer Drugs; 2007 Mar; 18(3):255-61. PubMed ID: 17264756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic bladder cancer: anything new?
    CalabrĂ² F; Sternberg CN
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):304-9. PubMed ID: 22643704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitors in children with malignant gliomas.
    Herrington B; Kieran MW
    Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer.
    Barocas DA; Clark PE
    Curr Opin Oncol; 2008 May; 20(3):307-14. PubMed ID: 18391631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer: from molecular pathogenesis to targeted therapy.
    Strimpakos A; Saif MW; Syrigos KN
    Cancer Metastasis Rev; 2008 Sep; 27(3):495-522. PubMed ID: 18427734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line therapy in bladder cancer.
    Bachner M; De Santis M
    Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
    Awada A; Mano M; Hendlisz A; Piccart M
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.